124 related articles for article (PubMed ID: 3037554)
1. Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia.
Bitterman H; Lefer DJ; Lefer AM
Proc Soc Exp Biol Med; 1987 Jul; 185(3):262-6. PubMed ID: 3037554
[TBL] [Abstract][Full Text] [Related]
2. CGS-12970, a thromboxane synthetase inhibitor, limits ischemic damage following coronary artery occlusion.
Hock CE; Lefer AM
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):285-94. PubMed ID: 3755540
[TBL] [Abstract][Full Text] [Related]
3. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat.
Smith EF; Egan JW; Goodman FR; Zimmerman MB; Webb RL; Ribeiro LG
Pharmacology; 1988; 37(4):254-63. PubMed ID: 2973611
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia.
Hock CE; Brezinski ME; Lefer AM
Eur J Pharmacol; 1986 Mar; 122(2):213-9. PubMed ID: 3011442
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
Bitterman H; Phillips GR; Dragon G; Lefer AM
J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
[TBL] [Abstract][Full Text] [Related]
6. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats.
Brezinski ME; Yanagisawa A; Darius H; Lefer AM
Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159
[TBL] [Abstract][Full Text] [Related]
7. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist.
Nichols WW; Mehta J; Wargovich TJ; Franzini D; Lawson D
Angiology; 1989 Mar; 40(3):209-21. PubMed ID: 2537051
[TBL] [Abstract][Full Text] [Related]
8. Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction.
Hock CE; Phillips GR; Lefer AM
Prostaglandins Leukot Med; 1985 Mar; 17(3):339-46. PubMed ID: 3857643
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
Lefer AM; Mentley R; Sun JZ
Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Levens NR; Ksander GM; Zimmerman MB; Mullane KM
Hypertension; 1989 Jan; 13(1):51-62. PubMed ID: 2910814
[TBL] [Abstract][Full Text] [Related]
11. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction.
Hock CE; Ribeiro LG; Lefer AM
Am Heart J; 1985 Feb; 109(2):222-8. PubMed ID: 2981461
[TBL] [Abstract][Full Text] [Related]
12. Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion.
O'Connor KM; Friehling TD; Kelliher GJ; MacNab MW; Wetstein L; Kowey PR
Am Heart J; 1986 Apr; 111(4):683-8. PubMed ID: 3953390
[TBL] [Abstract][Full Text] [Related]
13. Beneficial actions of the thromboxane receptor antagonist, AH-23,848, in acute myocardial ischemia.
Brezinski ME; Osborne JA; Yanagisawa A; Lefer AM
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):703-9. PubMed ID: 2966270
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.
Levens NR; Cóte D; Ksander G
J Pharmacol Exp Ther; 1991 Oct; 259(1):219-27. PubMed ID: 1920118
[TBL] [Abstract][Full Text] [Related]
15. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia.
Leprán I; Lefer AM
Basic Res Cardiol; 1985; 80(2):135-41. PubMed ID: 4039929
[TBL] [Abstract][Full Text] [Related]
16. Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor.
Burke SE; DiCola G; Lefer AM
J Cardiovasc Pharmacol; 1983; 5(5):842-7. PubMed ID: 6195474
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin-converting enzyme inhibition on changes in left ventricular myocardial creatine kinase system after myocardial infarction: their relation to ventricular remodeling and function.
Hironaka E; Hongo M; Azegami M; Yanagisawa S; Owa M; Hayama M
Jpn Heart J; 2003 Jul; 44(4):537-46. PubMed ID: 12906035
[TBL] [Abstract][Full Text] [Related]
18. The effects of nifedipine on acute experimental myocardial ischemia and infarction in dogs.
Selwyn AP; Welman E; Fox K; Horlock P; Pratt T; Klein M
Circ Res; 1979 Jan; 44(1):16-23. PubMed ID: 758229
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of KW-3049, a new 1,4-dihydropyridine calcium antagonist, on the reduction of myocardial creatine kinase activity and high-energy phosphate content in rats subjected to coronary artery ligation.
Karasawa A; Kubo K
J Pharmacobiodyn; 1988 Nov; 11(11):722-9. PubMed ID: 3236204
[TBL] [Abstract][Full Text] [Related]
20. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
